Daraxonrasib cuts death risk 60% in Phase 3 pancreatic cancer trial

The oral RAS(ON) inhibitor extended median overall survival to 13.2 months versus 6.7 months with chemotherapy in previously treated pancreatic cancer. An early-phase first-line combination produced a 60.7% response rate.

By Hana Sorensen, Biotech and trials correspondent
. 2-minute read.
Illustration: Revolution Medicines headquarters
Illustration: Clinical Observer

Revolution Medicines’ daraxonrasib, an oral multi-selective RAS(ON) inhibitor, reduced the risk of death by 60% compared with investigator-choice chemotherapy in the Phase 3 RASolute 302 trial of previously treated metastatic pancreatic adenocarcinoma, CASRAI reported on Friday. The randomized, open-label trial enrolled adults whose disease progressed after exactly one prior systemic line and who had an ECOG score of 0 or 1; median overall survival was 13.2 months with daraxonrasib 300 mg once daily versus 6.7 months with standard cytotoxic regimens (hazard ratio 0.40, 95% confidence interval 0.32 to 0.51; p<0.0001). Progression-free survival was a median of 7.2 months versus 3.6 months (hazard ratio 0.49, p<0.0001), and confirmed objective response rates were 30% to 32% versus 10% to 11%. Severe treatment-related side effects and drug discontinuations were less frequent with daraxonrasib than with chemotherapy; the most common daraxonrasib toxicities were mild rash, mouth sores, and diarrhea. The FDA and EMA have advanced formal regulatory reviews, with Fast Track designation supporting the agent.

In a EurekAlert! release from the 38th EORTC-NCI-AACR Symposium in Barcelona, researchers reported early-phase first-line data for daraxonrasib combined with gemcitabine and nab-paclitaxel in previously untreated metastatic pancreatic adenocarcinoma. Standard chemotherapy for untreated metastatic pancreatic cancer leads to tumour shrinkage in 23% to 42% of patients, median overall survival of about 8 to 11 months, and five-year survival of 3%, the release noted. The phase I/II RMC-GI-102 trial used 200 mg oral daraxonrasib daily with intravenous gemcitabine 1,000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1 and 15 of each cycle. By 28 September 2026, the combination had been given to 61 patients; median follow-up was 18.3 months (range, 13.1–23.7). Objective response occurred in 60.7% of patients, with complete responses in 8.2% and disease control in 90.2%; median progression-free survival reached 12.8 months, and 12-month overall survival was 76.6%. The release said the early-phase study had no chemotherapy-alone comparator. Principal investigator Dr Wungki Park said, "However, this is an early-phase study, and the results must be interpreted carefully because patients were not compared with patients receiving chemotherapy alone." The Phase 3 RASolute-303 trial is now evaluating daraxonrasib alone and together with gemcitabine plus nab-paclitaxel versus chemotherapy alone in first-line disease.

Sources: CASRAI, EurekAlert!

Hana SorensenBiotech and trials correspondent

Hana Sorensen covers drug developers, clinical trials and their results for Clinical Observer. Hana writes from trial registries, company filings, preprints and published reporting, and links every source.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.